Faculty Opinions recommendation of MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

2008 ◽  
Author(s):  
Janine Wechsler ◽  
Dimitri Salameire
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Lymphoproliferative Disorders ◽  
Lymphomatoid Papulosis ◽  
Large Cell Lymphoma

scholarly journals EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

Blood ◽  
2011 ◽  
Vol 118 (15) ◽  
pp. 4024-4035 ◽  
Author(s):  
Werner Kempf ◽  
Katrin Pfaltz ◽  
Maarten H. Vermeer ◽  
Antonio Cozzio ◽  
Pablo L. Ortiz-Romero ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
The United States ◽  
Lymphoproliferative Disorders ◽  
Cutaneous Lymphoma ◽  
European Organization ◽  
Lymphomatoid Papulosis ◽  
Cutaneous Lymphomas ◽  
Large Cell Lymphoma

AbstractPrimary cutaneous CD30+ lymphoproliferative disorders (CD30+ LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30+ LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30+ LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30+ LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30+ LPDs.

scholarly journals A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders

2009 ◽  
Vol 15 (19) ◽  
pp. 6217-6224 ◽  
Author(s):  
Madeleine Duvic ◽  
Sunil A. Reddy ◽  
Lauren Pinter-Brown ◽  
Neil J. Korman ◽  
John Zic ◽  
...  
Keyword(s):  
Phase Ii ◽  
Anaplastic Large Cell Lymphoma ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Lymphoproliferative Disorders ◽  
Large Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document